21st Austria weekly - Erste Group; Marinomed (28/02/2025)

02.03.2025

Erste Group: Erste Group Bank AG posted an operating result of 5.9 billion euros (+6.6%) in 2024 on the back of strong growth in customer business. The net result attributable to owners of the parent rose to EUR 3,125 million (EUR 2,998 million) on the back of the strong operating result.Customer loans rose significantly to 218.1 billion euros (+4.9%), with growth dynamics slightly stronger in Central and Eastern Europe (CEE). After somewhat weaker demand in the first half of the year, the appetite for loans grew in the fourth quarter. Deposits too increased to 241.7 billion euros (+3.8%). “Our results show that we are active in Europe's growth region, with two-thirds of our profits coming from our banks in Central and Eastern Europe. The pursuit of prosperity here remains unbroken, despite the strong convergence over the past 20 years. This region is also where future potential lies. In view of the major geopolitical changes taking place, Europe needs to grow closer together,” says Peter Bosek, CEO of Erste Group.
Erste Group: weekly performance: -2.50%

Marinomed: Marinomed Biotech AG (VSE:MARI) announces the successful closing of the sale of the Carragelose business to French CDMO (contract development and manufacturing organization) Unither Pharmaceuticals. All necessary conditions for completing the transaction have been met: The contract provides for upfront and milestone payments in total of up to EUR 20 million, including an upfront payment of up to EUR 5 million associated with closing of the deal. Further payments depend on the achievement of defined commercial and operational targets over the next two years. The agreement provides for the transfer of the entire Carragelose portfolio, including all associated agreements and business relations. As part of the agreement, Marinomed and Unither also entered into a transition service agreement covering services in the areas of regulatory affairs, business development or research & development.
Marinomed Biotech: weekly performance: -2.80%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (28/02/2025)


Partners









latest 21st Austria

21st Austria weekly - Erste Group; Marinomed (28/02/2025)


02.03.2025, 2113 Zeichen



Erste Group: Erste Group Bank AG posted an operating result of 5.9 billion euros (+6.6%) in 2024 on the back of strong growth in customer business. The net result attributable to owners of the parent rose to EUR 3,125 million (EUR 2,998 million) on the back of the strong operating result.Customer loans rose significantly to 218.1 billion euros (+4.9%), with growth dynamics slightly stronger in Central and Eastern Europe (CEE). After somewhat weaker demand in the first half of the year, the appetite for loans grew in the fourth quarter. Deposits too increased to 241.7 billion euros (+3.8%). “Our results show that we are active in Europe's growth region, with two-thirds of our profits coming from our banks in Central and Eastern Europe. The pursuit of prosperity here remains unbroken, despite the strong convergence over the past 20 years. This region is also where future potential lies. In view of the major geopolitical changes taking place, Europe needs to grow closer together,” says Peter Bosek, CEO of Erste Group.
Erste Group: weekly performance: -2.50%

Marinomed: Marinomed Biotech AG (VSE:MARI) announces the successful closing of the sale of the Carragelose business to French CDMO (contract development and manufacturing organization) Unither Pharmaceuticals. All necessary conditions for completing the transaction have been met: The contract provides for upfront and milestone payments in total of up to EUR 20 million, including an upfront payment of up to EUR 5 million associated with closing of the deal. Further payments depend on the achievement of defined commercial and operational targets over the next two years. The agreement provides for the transfer of the entire Carragelose portfolio, including all associated agreements and business relations. As part of the agreement, Marinomed and Unither also entered into a transition service agreement covering services in the areas of regulatory affairs, business development or research & development.
Marinomed Biotech: weekly performance: -2.80%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (28/02/2025)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #888: ATX zurück bei 4000, Banken und Pierer Mobility top, Wienerberger beim Osterreichischen Aktientag




 

Bildnachweis

Aktien auf dem Radar:Frequentis, Palfinger, Amag, Semperit, Rosenbauer, RHI Magnesita, Verbund, CPI Europe AG, VIG, OMV, Telekom Austria, Uniqa, Wienerberger, Erste Group, SBO, Flughafen Wien, Josef Manner & Comp. AG, Wolford, Agrana, Oberbank AG Stamm, Pierer Mobility, CA Immo, Kapsch TrafficCom, Polytec Group, Strabag, Österreichische Post, Andritz, Continental, Sartorius, Dow Jones, 3M.


Random Partner

EVN
Die EVN ist ein internationales, börsennotiertes Energie- und Umweltdienstleistungsunternehmen mit Sitz in Niederösterreich und bietet in ihrem Heimmarkt auf Basis modernster Infrastruktur Strom, Gas, Wärme, Trinkwasserver- sowie Abwasserentsorgung und thermische Abfallverwertung „aus einer Hand“. Das Energiegeschäft im Ausland umfasst den Stromverkauf an Endkund*innen in Deutschland, Bulgarien und Nordmazedonien, den Gasverkauf an Endkund*innen in Kroatien, sowie die Stromproduktion in Nordmazedonien, Bulgarien, Albanien und Deutschland.

>> Besuchen Sie 60 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten


h